Penpulimab vs Retifanlimab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline

Penpulimab

Marketed by Akeso and partners

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Reliable signal

NCT03866993 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled Phase 3 trial in 350 patients with advanced squamous non-small-cell lung cancer, all of whom also received paclitaxel and carboplatin. An independent radiology committee assessed progression-free survival in two primary populations: all randomized patients and the PD-L1-positive subgroup. Penpulimab improved progression-free survival in both populations (median 7.6 vs 4.2 months overall and 8.1 vs 4.2 months in PD-L1-positive patients, both p<0.0001), so the trial met its primary endpoint. The figures come from the peer-reviewed Lancet Respiratory Medicine paper.

Reported efficacy

Progression-free survival (PFS) in intent-to-treat (ITT) population, assessed by Independent Radiologist Review Committee(IRRC) in accordance with RECIST v1.1 (Up to approximately 2 years); PFS in PD-L1-selected population, assessed by IRRC in accordance with RECIST v1.1 (Up to approximately 2 years): Primary 1, IRRC-assessed PFS in the ITT population (final analysis): median 7.6 months (95% CI 6.8 to 9.6) penpulimab + chemotherapy vs 4.2 months (95% CI 4.2 to 4.3) placebo + chemotherapy; HR 0.43 (95% CI 0.33 to 0.56); p<0.0001, met. Primary 2, IRRC-assessed PFS in the PD-L1-positive subgroup: median 8.1 vs 4.2 months; HR 0.37 (95% CI 0.27 to 0.52); p<0.0001, met. (met)

Result source: NCT03866993

Retifanlimab

Marketed by Incyte

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Reliable signal

NCT04205812 · Phase 3 · completed

Participants were randomly assigned and double-blinded to receive retifanlimab or placebo with standard chemotherapy, with 391 in the retifanlimab group and 192 in the control group. The hard clinical primary endpoint of overall survival was met, favoring retifanlimab (hazard ratio 0.75; p=0.0042).

Next expected readout: December 2027 · NCT07219576 (registry estimate)

Reported efficacy

Overall Survival (up to 39.1 months): Overall Survival (up to 39.1 months): Retifanlimab + Chemotherapy 18.1 months (95% CI 16.2 to 21) vs Placebo + Chemotherapy 13.4 months (95% CI 11 to 16.7) (met)

Result source: NCT04205812

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointPenpulimabRetifanlimab
PFS, median8.6 vs 4.2a+4.4 vs placeboNCT038669937.7 vs 5.5+2.2 vs placebon 391NCT04205812
OS, median—Not posted · NCT0386699318.1 vs 13.4+4.7 vs placebon 391NCT04205812
ORR—Not posted · NCT0386699351.7% vs 38.5%+13.2 vs placebon 391NCT04205812
Duration of response, median—Not posted · NCT0386699312.7 vs 6.1+6.6 vs placebon 202NCT04205812

PFS, median

Penpulimab
8.6 vs 4.2a+4.4 vs placeboNCT03866993
Retifanlimab
7.7 vs 5.5+2.2 vs placebon 391NCT04205812

OS, median

Penpulimab
—Not posted · NCT03866993
Retifanlimab
18.1 vs 13.4+4.7 vs placebon 391NCT04205812

ORR

Penpulimab
—Not posted · NCT03866993
Retifanlimab
51.7% vs 38.5%+13.2 vs placebon 391NCT04205812

Duration of response, median

Penpulimab
—Not posted · NCT03866993
Retifanlimab
12.7 vs 6.1+6.6 vs placebon 202NCT04205812
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Penpulimab: 0 of 4 rows · Retifanlimab: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricPenpulimabRetifanlimab
Dropout rate—
100%Retifanlimab + Chemotherapy
NCT04205812 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 1 more result
—Retifanlimab Monotherapy
NCT04205812 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Discontinued due to AEs—
—Retifanlimab + Chemotherapy
NCT04205812 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 1 more result
—Retifanlimab Monotherapy
NCT04205812 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Serious AEs—
40.6%Retifanlimab + Chemotherapy
NCT04205812 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 1 more result
20.3%Retifanlimab Monotherapy
NCT04205812 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Most frequent reported AEs—
anaemia 60.4% (placebo 56.8%)
decreased appetite 22.6% (placebo 13.2%)
neutrophil count decreased 21.6% (placebo 17.4%)
NCT04205812 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 1 more result
aspartate aminotransferase increased 23.7% (placebo 22.1%)
anaemia 22% (placebo 56.8%)
alanine aminotransferase increased 15.3% (placebo 23.7%)
NCT04205812 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Retifanlimab

Overall Survival 18.1 vs 13.4 placebo months
time to event · months
NCT04205812 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
ORR 51.7% (n=391) vs 38.5% (n=192) placebo
responder rate · % of participants
NCT04205812 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Duration of Response 12.7 vs 6.1 placebo months
time to event · months
NCT04205812 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Penpulimab's landscape · Retifanlimab's landscape